Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of tislelizumab- and/or pamiparib-containing treatment in advanced malignancies
2019-002554-23Phase 3Active
- Sponsor
- BeiGene
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tislelizumab and pamiparib in Non-hematologic malignancy and hematopoietic malignancies, sponsored by BeiGene. Primary endpoint: Long-term safety. Started May 2020; status: active.
02
Drugs
tislelizumabpamiparib
03
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on 2019-002554-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002554-23.